NeuroMetrix CEO Interviewed on CEONEWS.TvWALTHAM, Mass.--(BUSINESS WIRE)--Mar. 26, 2012--
NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on
the diagnosis and treatment of neurological complications of diabetes
announced that Chief Executive Officer
Shai N. Gozani, M.D., Ph.D. has
been interviewed on CEONEWS.Tv, a financial news network. The interview
is available at:
http://www.ceonews.tv/nuro/
In the interview, Dr. Gozani discussed his vision for NeuroMetrix and
the company’s early success with NC-stat® DPNCheck™, a fast,
accurate, and quantitative test for diabetic peripheral neuropathy
(DPN). DPN is a nerve disease that affects over 50% of patients with
diabetes and can lead to foot ulcers and amputation. Dr. Gozani reviewed
the market opportunity and most important market segments. He also
outlined the company’s R&D pipeline and important milestones for 2012.
The company recently completed an $8.5M public offering to fund its
commercial and product development efforts. NeuroMetrix was founded in
1996 and has been publicly traded on Nasdaq since 2004, he noted.
NeuroMetrix was also recently featured in the Conservative Speculator
which can be viewed at http://wallstreetcorner.com/cs/NURO.pdf
About NeuroMetrix
NeuroMetrix is a medical device company focused on the diagnosis and
treatment of the neurological complications of diabetes. The Company
currently markets products for the detection, diagnosis, and monitoring
of diabetic neuropathies such as diabetic peripheral neuropathy and
median neuropathy (carpal tunnel syndrome). For more information, please
visit http://www.neurometrix.com.
Source: NeuroMetrix, Inc.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
Chief
Financial Officer
neurometrix.ir@neurometrix.com
